HIV Care Continuum

Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.

Sept. 17, 2020: HIV prevalence gaps between Latinx people and non-Latinx white people; Obamacare awareness and perceptions among HIV clinicians; the relationship between pain and HIV; cancer mortality trends among PLWH.

As a proud media partner of the 2020 SYNChronicity conference, we'll be covering some of the dozens of conference sessions taking place from Sep. 8 through Sep. 11—and you can come say hi to us at our virtual booth!

Sep. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.

Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.

What starts as an assumption of patient incompetence results in the erasure of autonomy from Black patients.

July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.

July 23, 2020: Depression and HIV risk mitigation among MSM; a consistent HIV provider is good for CD4 and viral load; spirituality and HIV prevention; HCV treatment access and reinfection risk.

Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.